Janux Therapeutics (JANX) Preferred Stock Liabilities (2020 - 2021)
Janux Therapeutics (JANX) posted quarterly Preferred Stock Liabilities of $77.3 million for Q1 2021, up 257.69% quarter-over-quarter from $21.6 million in Q4 2020.
Powered by 
Analysis
Janux Therapeutics (JANX) Preferred Stock Liabilities (2020 - 2021) Analysis & Trends
Janux Therapeutics (JANX) has reported Preferred Stock Liabilities for 2 consecutive years, with $77.3 million the latest figure, recorded in Q1 2021.
- In Q1 2021, Preferred Stock Liabilities changed N/A year-over-year to $77.3 million; the TTM figure through Mar 2021 stood at $77.3 million (changed N/A YoY), while the FY2020 annual figure was $21.6 million, changed N/A from the prior year.
- Preferred Stock Liabilities climbed to $77.3 million in Q1 2021 per JANX's latest filing, from $21.6 million in the prior quarter.
- Across five years, Preferred Stock Liabilities topped out at $77.3 million in Q1 2021 and bottomed at $17.1 million in Q2 2020.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Preferred Stock Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | - |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Janux Therapeutics | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Mar 31, 2021 | 77.35 Mn |
| Dec 31, 2020 | 21.62 Mn |
| Sep 30, 2020 | 17.13 Mn |
| Jun 30, 2020 | 17.13 Mn |